×
About 5,983 results

ALLMedicine™ Gastrointestinal Cancers Center

Research & Reviews  1,124 results

Adding SBRT to sorafenib boosts survival in liver cancer
https://www.mdedge.com/hematology-oncology/article/260884/gastrointestinal-cancer/adding-sbrt-sorafenib-boosts-survival
Roxanne Nelson, RN, BSN

Jan 27th, 2023 - SAN FRANCISCO – Adding stereotactic body radiation therapy (SBRT) to sorafenib produced better outcomes among patients with hepatocellular carcinoma (HCC) than sorafenib alone, according to new findings. The use of SBRT in this setting improved bo.

Chemerin and Chemokine-like Receptor 1 Are Not Prognostic in Colorectal Carcinoma.
https://doi.org/10.21873/anticanres.16225
Anticancer Research; Weber F, Jung R et. al.

Jan 26th, 2023 - Colorectal carcinoma is a commonly diagnosed malignancy. The chemoattractant protein chemerin was shown to regulate immune response, angiogenesis, and cell migration and has a role in gastrointestinal cancers. Chemerin and its receptor chemokine-l...

Palliative radiotherapy successfully reduces end-stage liver cancer pain
https://www.mdedge.com/hematology-oncology/article/260791/gastrointestinal-cancer/palliative-radiotherapy-successfully
Randy Dotinga

Jan 25th, 2023 - Most patients with end-stage hepatocellular carcinoma experience pain, but when it’s severe, how best to control the pain is debatable. A number of studies, including one recently presented at the ASCO Gastrointestinal Cancers Symposium 2023, show.

Association of polypharmacy and potential drug-drug interactions with adverse treatment...
https://doi.org/10.1002/cncr.34642
Cancer Mohamed MR, Mohile SG et. al.

Jan 25th, 2023 - Polypharmacy is common in older adults who are starting cancer treatment and is associated with an increased risk of potentially inappropriate medications (PIMs) and potential drug-drug interactions (PDIs). The authors evaluated the association of...

Development and Validation of a Machine Learning Model for Detection and Classification...
https://doi.org/10.1001/jamanetworkopen.2022.52553
JAMA Network Open; Li Z, Jiang Y et. al.

Jan 25th, 2023 - Tertiary lymphoid structures (TLSs) are associated with a favorable prognosis and improved response to cancer immunotherapy. The current approach for evaluation of TLSs is limited by interobserver variability and high complexity and cost of specia...

see more →

Guidelines  2 results

AGA Clinical Practice Update on Surveillance After Pathologically Curative Endoscopic S...
https://doi.org/10.1053/j.gastro.2021.08.058
Gastroenterology Wang AY, Hwang JH et. al.

Oct 26th, 2021 - The purpose of this American Gastroenterological Association (AGA) Institute Clinical Practice Update was to review the available evidence and provide expert advice regarding surveillance using endoscopy and other relevant modalities after removal...

Screening and surveillance in hereditary gastrointestinal cancers: Recommendations from...
https://doi.org/10.1016/j.ejca.2018.09.004
European Journal of Cancer (Oxford, England : 1990); Vangala DB, Cauchin E et. al.

Oct 21st, 2018 - Patients with hereditary gastrointestinal (GI) cancers represent a substantial fraction of the overall affected population. Although awareness for hereditary GI cancer syndromes is on the rise, identification of patients and measures of surveillan...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  81 results

Acquisition of Blood and Tumor Tissue Samples From Patients With Gastrointestinal Cancer
https://clinicaltrials.gov/ct2/show/NCT01313442

Jan 13th, 2023 - BACKGROUND: Numerous recent therapeutic advances have changed standard treatment options for patients with GI cancer. These include newer chemotherapeutic agents in addition to established proof of principle for anti-angiogenic agents. The burden ...

A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers
https://clinicaltrials.gov/ct2/show/NCT05087992

Jan 10th, 2023 - This study is open to adults with advanced colorectal cancer or with advanced pancreatic cancer. The study has 2 parts. In the first part, participants with colorectal cancer get a medicine called BI 905711 combined with chemotherapy and bevacizum...

Remote Monitoring in Cancer Care: A Platform Study
https://clinicaltrials.gov/ct2/show/NCT05018208

Jan 9th, 2023 - PRIMARY OBJECTIVES: I. Develop patient-specific algorithms to predict the trajectory of cytokine release syndrome (CRS) and or neurotoxicity and time to escalation of medical intervention is needed. (Arm 1) II. Establish the validity for the use o...

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
https://clinicaltrials.gov/ct2/show/NCT04430738

Jan 6th, 2023 - This trial studies tucatinib to find out if it is safe when given with trastuzumab and other anti-cancer drugs (pembrolizumab, FOLFOX, and CAPOX). It will look at what side effects happen when participants take this combination of drugs. A side ef...

2 Versus 6 Hour Oxaliplatin Infusions in Patients With Gastrointestinal Cancers
https://clinicaltrials.gov/ct2/show/NCT03800693

Dec 13th, 2022 - PRIMARY OBJECTIVE: I. To determine the effect of 2 versus 6-hour oxaliplatin infusion time on the difference in severity of sensory neuropathy as measured by patient reported outcome (PRO) scores on the European Organization for Research and Treat...

see more →

News  1,185 results

Adding SBRT to sorafenib boosts survival in liver cancer
https://www.mdedge.com/hematology-oncology/article/260884/gastrointestinal-cancer/adding-sbrt-sorafenib-boosts-survival
Roxanne Nelson, RN, BSN

Jan 27th, 2023 - SAN FRANCISCO – Adding stereotactic body radiation therapy (SBRT) to sorafenib produced better outcomes among patients with hepatocellular carcinoma (HCC) than sorafenib alone, according to new findings. The use of SBRT in this setting improved bo.

Palliative radiotherapy successfully reduces end-stage liver cancer pain
https://www.mdedge.com/hematology-oncology/article/260791/gastrointestinal-cancer/palliative-radiotherapy-successfully
Randy Dotinga

Jan 25th, 2023 - Most patients with end-stage hepatocellular carcinoma experience pain, but when it’s severe, how best to control the pain is debatable. A number of studies, including one recently presented at the ASCO Gastrointestinal Cancers Symposium 2023, show.

Women Missing Out on Opportunities From Advisory Boards
https://www.medscape.com/viewarticle/984935

Dec 2nd, 2022 - Being on an advisory board of a pharmaceutical company gives oncologists a chance to influence clinical trials and drug commercialization and to "inform decisions that affect the oncology community," say the authors of a new analysis, which found ...

Forging a New Field
https://www.onclive.com/view/forging-a-new-field

Nov 24th, 2022 - Jennifer Temel, MD, has a calming demeanor and an easy laugh. It is easy to see how patients feel comforted in her presence, although she shared that she feels most at ease when with small groups of people. A truly gentle spirit, she is a lifelong...

Innovative Trajectory Built From Tradition
https://www.onclive.com/view/innovative-trajectory-built-from-tradition

Nov 23rd, 2022 - From a young age, Roy S. Herbst, MD, PhD, was fascinated by physiology. He was an avid learner and successful student in many academic subjects, but he had a singular passion for science that grew stronger throughout his childhood and young adult ...

see more →